Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Explore the clinical features, complex burden, and underlying mechanisms of PN.

Dr. Jason Hawkes details the role of IL-4 and IL-13 in the pathophysiology of CSU at EADV 2025
Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Professor Joost Meijer discusses the complex etiology and diagnosis of BP
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.
Experience this engaging presentation by Professors Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.